{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:20:21Z","timestamp":1778934021280,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"John C. Hench Foundation"},{"DOI":"10.13039\/100008664","name":"Juvenile Diabetes Research Foundation","doi-asserted-by":"publisher","award":["JDRF2-SRA-2016-314-S-B"],"award-info":[{"award-number":["JDRF2-SRA-2016-314-S-B"]}],"id":[{"id":"10.13039\/100008664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.vaccine.2018.10.101","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T14:24:26Z","timestamp":1541687066000},"page":"8008-8018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors affecting Salmonella-based combination immunotherapy for prevention of type 1 diabetes in non-obese diabetic mice"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-2858","authenticated-orcid":false,"given":"Mohamed I.","family":"Husseiny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiting","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Mbongue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayelet","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad","family":"Kandeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.101_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007641","article-title":"The pathogenesis and natural history of type 1 diabetes","volume":"2","author":"Atkinson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2018.10.101_b0010","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db10-1201","article-title":"Defective differentiation of regulatory Foxp3+ T cells by small-intestinal dendritic cells in patients with type 1 diabetes","volume":"60","author":"Badami","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2018.10.101_b0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2010.04153.x","article-title":"Group I-JTDCTA. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 diabetes combination therapy assessment group","volume":"160","author":"Matthews","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.10.101_b0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2013.05.001","article-title":"Anti-CD3 clinical trials in type 1 diabetes mellitus","volume":"149","author":"Daifotis","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40259-013-0060-3","article-title":"Treg vaccination in autoimmune type 1 diabetes","volume":"28","author":"Serr","year":"2014","journal-title":"Biodrugs"},{"key":"10.1016\/j.vaccine.2018.10.101_b0035","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s11892-013-0415-7","article-title":"Antigen-based vaccination and prevention of type 1 diabetes","volume":"13","author":"Harrison","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.vaccine.2018.10.101_b0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clim.2010.10.004","article-title":"GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients","volume":"138","author":"Hjorth","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0045","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2337\/dc11-0523","article-title":"Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial","volume":"34","author":"Vehik","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vaccine.2018.10.101_b0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.101_b0055","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.10.101_b0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2011.01017.x","article-title":"Oral tolerance","volume":"241","author":"Weiner","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2018.10.101_b0065","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1172\/JCI60530","article-title":"Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice","volume":"122","author":"Takiishi","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.10.101_b0070","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.2337\/db13-1236","article-title":"Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice","volume":"63","author":"Robert","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2018.10.101_b0075","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.vaccine.2014.02.070","article-title":"An oral vaccine for type 1 diabetes based on live attenuated Salmonella","volume":"32","author":"Husseiny","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.101_b0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000100515","article-title":"Vivotif\u2013a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens","volume":"53","author":"Gentschev","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.vaccine.2018.10.101_b0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2407-12-361","article-title":"Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer","volume":"12","author":"Niethammer","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2018.10.101_b0090","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.vaccine.2004.11.035","article-title":"Evaluation of an intracellular-activated promoter for the generation of live Salmonella recombinant vaccines","volume":"23","author":"Husseiny","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.101_b0095","doi-asserted-by":"crossref","first-page":"6965","DOI":"10.1128\/IAI.00648-06","article-title":"The translocated Salmonella effector proteins SseF and SseG interact and are required to establish an intracellular replication niche","volume":"74","author":"Deiwick","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.10.101_b0100","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1600-0854.2006.00454.x","article-title":"Functional dissection of SseF, a type III effector protein involved in positioning the Salmonella-containing vacuole","volume":"7","author":"Abrahams","year":"2006","journal-title":"Traffic"},{"key":"10.1016\/j.vaccine.2018.10.101_b0105","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/ijc.24957","article-title":"Novel cancer vaccine based on genes of Salmonella pathogenicity island 2","volume":"126","author":"Xiong","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2018.10.101_b0110","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/IAI.00298-10","article-title":"Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines","volume":"78","author":"Xu","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.10.101_b0115","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1128\/IAI.06056-11","article-title":"Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens","volume":"80","author":"Hegazy","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.10.101_b0120","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/0008-5472.CAN-14-1169","article-title":"Effective cancer vaccine platform based on attenuated Salmonella and a type III secretion system","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.10.101_b0125","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.78.23.12901-12909.2004","article-title":"Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1","volume":"78","author":"Baud","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1089\/aid.2006.0098","article-title":"Oral attenuated Salmonella enterica serovar Typhimurium vaccine expressing codon-optimized HIV type 1 Gag enhanced intestinal immunity in mice","volume":"23","author":"Tsunetsugu-Yokota","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2018.10.101_b0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3920\/BM2014.0083","article-title":"Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis","volume":"6","author":"Robert","year":"2015","journal-title":"Benef Microbes"},{"key":"10.1016\/j.vaccine.2018.10.101_b0140","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1158\/0008-5472.CAN-10-4676","article-title":"Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors","volume":"71","author":"Manuel","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.10.101_b0145","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1084\/jem.20110574","article-title":"Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope","volume":"208","author":"Daniel","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.10.101_b0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaut.2012.04.005","article-title":"Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9\u201323 epitope and involves functional epitope spreading","volume":"39","author":"Prasad","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2018.10.101_b0155","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI31368","article-title":"Priming and effector dependence on insulin B: 9\u201323 peptide in NOD islet autoimmunity","volume":"117","author":"Nakayama","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.10.101_b0160","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.2337\/db11-1520","article-title":"Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells","volume":"61","author":"Kronenberg","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2018.10.101_b0165","first-page":"3390","article-title":"CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope","volume":"118","author":"Skowera","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.10.101_b0170","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/dmrr.941","article-title":"Therapy with GAD in diabetes","volume":"25","author":"Ludvigsson","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.vaccine.2018.10.101_b0175","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2337\/db10-0630","article-title":"Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential","volume":"59","author":"Peakman","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2018.10.101_b0180","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12046","article-title":"Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation","volume":"15","author":"Schneider","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.vaccine.2018.10.101_b0185","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2337\/db15-1625","article-title":"Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells","volume":"66","author":"Takiishi","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2018.10.101_b0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.vaccine.2005.11.020","article-title":"Recombinant vaccines based on translocated effector proteins of Salmonella pathogenicity island 2","volume":"25","author":"Husseiny","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.101_b0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1615\/CritRevImmunol.v30.i3.30","article-title":"New technologies in using recombinant attenuated Salmonella vaccine vectors","volume":"30","author":"Curtiss","year":"2010","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0205","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.4049\/jimmunol.171.5.2270","article-title":"Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion","volume":"171","author":"Goudy","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/clin.1994.1068","article-title":"Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse","volume":"71","author":"Pennline","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0215","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.4049\/jimmunol.165.12.7330","article-title":"A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes","volume":"165","author":"Balasa","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0220","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.4049\/jimmunol.165.5.2841","article-title":"Islet-specific expression of IL-10 promotes diabetes in nonobese diabetic mice independent of Fas, perforin, TNF receptor-1, and TNF receptor-2 molecules","volume":"165","author":"Balasa","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.101_b0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-1119(91)90366-J","article-title":"Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli","volume":"100","author":"Wang","year":"1991","journal-title":"Gene"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T05:39:38Z","timestamp":1720762778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18314981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":45,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0264410X18314981"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.101","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors affecting Salmonella-based combination immunotherapy for prevention of type 1 diabetes in non-obese diabetic mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}